Skip to content
Trogarzo(ibalizumab)
Trogarzo (ibalizumab) is an antibody pharmaceutical. Ibalizumab was first approved as Trogarzo on 2018-03-06. It is used to treat HIV infections in the USA. It has been approved in Europe to treat HIV infections. The pharmaceutical is active against T-cell surface glycoprotein CD4.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
urogenital diseasesD000091642
immune system diseasesD007154
Trade Name
FDA
EMA
Trogarzo
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Ibalizumab
Tradename
Proper name
Company
Number
Date
Products
Trogarzoibalizumab-uiykTheratechnologiesN-761065 RX2018-03-06
1 products
Labels
FDA
EMA
Brand Name
Status
Last Update
trogarzoBiologic Licensing Application2020-04-08
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
hiv infectionsEFO_0000764D015658B20
Agency Specific
FDA
EMA
Expiration
Code
ibalizumab, Trogarzo, Theratechnologies Inc.
2025-03-06Orphan excl.
Patent Expiration
No data
ATC Codes
J: Antiinfectives for systemic use
— J05: Antivirals for systemic use
— J05A: Direct acting antivirals
— J05AX: Other antivirals in atc
— J05AX23: Ibalizumab
HCPCS
Code
Description
J1746
Injection, ibalizumab-uiyk, 10 mg
Clinical
Clinical Trials
10 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv infectionsD015658EFO_0000764B20—21—25
HivD006678O98.7—12——3
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
InfectionsD007239EFO_00005441————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv-2D015498————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameIBALIZUMAB
INNibalizumab
Description
Ibalizumab (humanized mab)
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)IBALIZUMAB
Structure (InChI/SMILES or Protein Sequence)
>3O2D:H|ibalizumab heavy chain QVQLQQSGPEVVKPGASVKMSCKASGYTFTSYVIHWVRQKPGQGLDWIGYINPYNDGTDYDEKFKGKATLTSDTSTSTAY MELSSLRSEDTAVYYCAREKDNYATGAWFAYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVT VSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYG >3O2D:L|ibalizumab light chain DIVMTQSPDSLAVSLGERVTMNCKSSQSLLYSTNQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFSGSGSGTDFTLT ISSVQAEDVAVYYCQQYYSYRTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQ SGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
Identifiers
PDB3O2D, 7T0R
CAS-ID680188-33-4
RxCUI—
ChEMBL IDCHEMBL1743029
ChEBI ID—
PubChem CID—
DrugBankDB12698
UNII IDLT369U66CE (ChemIDplus, GSRS)
Target
Agency Approved
CD4
CD4
Organism
Homo sapiens
Gene name
CD4
Gene synonyms
NCBI Gene ID
920
Protein name
T-cell surface glycoprotein CD4
Protein synonyms
CD4, CD4 antigen (p55), CD4 receptor, T-cell surface antigen T4/Leu-3
Uniprot ID
Q9UDE5
Mouse ortholog
Cd4 (12504)
T-cell surface glycoprotein CD4 (P06332)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 424 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
50,071 adverse events reported
View more details